Select Page

NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) — Intrommune Therapeutics, a New York-based biotechnology company developing patient-friendly food allergy therapies for peanut and other food allergies delivered via the revolutionary oral mucosal immunotherapy treatment platform, is proud to announce its participation in three upcoming conferences: